hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-11 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== Principles of saw chain operation == Saw chains operate by being propelled around a guide bar, removing material from the kerf by cutting chips from the side and bottom. In order to operate properly, the depth to which each tooth cuts must be limited to avoid it binding in the wood. Scratcher chain, like the teeth on a hand saw, simply uses a multitude of teeth to prevent individual teeth from sinking too far in without undue pressure on the bar. Chipper chain, and all subsequent designs, incorporate a depth gauge (also known as a "raker") on each cutter link to limit depth of cut on each tooth. This has two distinct advantages over scratcher chain – it enables the use of fewer cutters per unit length of chain, which allows for shorter downtime for sharpening, and produces a more "open" chain layout, allowing far better clearance of chips and debris from the kerf. Individual depth gauges on each tooth also enable the use of skip chain. Skip or semi-skip chain has a further reduction in the number of teeth and is used for applications where much debris is produced, such as ripping or cross-cutting very large sections of wood. Skip chain also absorbs less power from the motor per unit length of chain than full-complement chain, allowing the use of a longer bar/chain combination on any given motor.
=== France === French authorities established two security zones around Évian-les-Bains, Neuvecelle and Publier from 11 to 17 June 2026. The red zone, around the main summit site, was reserved for people with a compelling reason to enter. The blue zone was accessible only to people holding a G7 pass issued by the prefecture. The French security operation mobilised more than 7,160 national police officers and 6,100 gendarmes in Haute-Savoie. Around 200 police officers were assigned to close protection for heads of state and government. The security perimeter covered approximately 1,670 km2 (640 sq mi), with additional support from around 900 military personnel and 830 customs officers. In total, nearly 16,000 police officers, gendarmes, military personnel, firefighters and customs officers were mobilised on the French side, with boats, motorcycles, drones, mounted units and dog units deployed as part of the operation. The Évian-les-Bains railway station was closed from 11 to 17 June 2026. Rail services between Thonon-les-Bains and Évian-les-Bains were suspended during the same period, with replacement buses requiring a G7 pass. More than 30 boats from the security forces were deployed on Lake Geneva as part of the French security arrangements. Security measures included restrictions on lake transport, including the temporary closure of the Évian-les-Bains ferry terminal for the CGN Évian-Lausanne service. Connections were redirected to Thonon-les-Bains and Lugrin, where a temporary terminal was arranged for the summit period.
=== Economic value === In the areas in which it was endemic, the emu was an important source of meat to Aboriginal Australians. They used the fat as bush medicine and rubbed it into their skin. It served as a valuable lubricant, was used to oil wooden tools and utensils such as the coolamon, and was mixed with ochre to make the traditional paint for ceremonial body adornment. Their eggs were also foraged for food. An example of how the emu was cooked comes from the Arrernte of Central Australia who called it Kere ankerre:
Mumps vaccines are vaccines which prevent mumps. When given to a majority of the population they decrease complications at the population level. Effectiveness when 90% of a population is vaccinated is estimated at 85%. Two doses are required for long term prevention. The initial dose is recommended between 12 and 18 months of age. The second dose is then typically given between two years and six years of age. Usage after exposure in those not already immune may be useful. Side effects are usually mild. It may cause "slight soreness and swelling" at the site of injection, parotisis and mild fever. More significant side effects are rare. Evidence is insufficient to link the vaccine to complications such as neurological effects (beyond "occasional orchitis and sensorineural deafness"). The vaccine should not be given to people who are pregnant or have very poor immune system function. Poor outcomes among children of mothers who received the vaccine during pregnancy, however, have not been documented. Even though the vaccine is developed in chicken cells, it is generally safe to give to those with egg allergies. Most of the developed world and many countries in the developing world include it in their immunization programs often in combination with measles and rubella vaccine known as MMR. A formulation with the previous three and the varicella (chickenpox) vaccine known as MMRV is also available. As of 2005, 110 countries provided the vaccine as part of their immunization programs.
Sources: en.wikipedia.org
=== Data management plan === The data management plan describes the activities to be conducted in the course of processing data. Key topics to cover include the SOPs to be followed, the clinical data management system (CDMS) to be used, description of data sources, data handling processes, data transfer formats and process, and quality control procedure
The problem of minimizing ET is an NP-hard problem. Even though the class of problems is NP-hard, in practice many instances of protein design can be solved exactly or optimized satisfactorily through heuristic methods.
In the United States, the FDA has approved pregabalin for adjunctive therapy for adults with partial onset seizures, management of postherpetic neuralgia and neuropathic pain associated with spinal cord injury and diabetic peripheral neuropathy, and the treatment of fibromyalgia. In Australia, the TGA has approved pregabalin for neuropathic pain in adults and epilepsy, it is not approved in Australia for generalized anxiety disorder or fibromyalgia. Pregabalin has also been approved in the European Union, the United Kingdom, and Russia for treatment of generalized anxiety disorder.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.